SCHEMBL134623

SCHEMBL134623

[2H]c1c(Cl)ccc(Cn2c(CCl)nc3ccccc32)c1[2H]

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
LMNA P02545 3/20 0.56
HIF1A Q16665 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
KCNH2 Q12809 2/20 0.56
NR1I2 O75469 1/20 0.56
ABCB11 O95342 1/20 0.56
ESR1 P03372 1/20 0.56
CYP1A2 P05177 1/20 0.56
PGR P06401 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
TSHR P16473 1/20 0.56
ADRA2B P18089 1/20 0.56
HTR2A P28223 1/20 0.56
CYP2C19 P33261 1/20 0.56
ADRA1A P35348 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95065 0.89 MEN1 (0.79) MEN1KMT2ALMNAHIF1ATDP1
Clemizole SCHEMBL3478439 0.84 HIF1A (0.82) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL103530 0.81 MEN1 (1.00) MEN1KMT2ALMNACYP1A2CYP3A4
Hydrochloric Acid SCHEMBL10353601 0.80 MEN1 (0.97) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL95019 0.80 MEN1 (0.60) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL11746981 0.79 MEN1 (0.77) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL10353548 0.78 KMT2A (0.71) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL10353116 0.78 KMT2A (0.76) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL8022214 0.77 LMNA (0.79) MEN1KMT2ALMNAHIF1ATDP1
SCHEMBL8366844 0.76 RAB9A (0.76) MEN1KMT2ALMNAHIF1ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058085-A1 Deuterium Modified Benzimidazoles CONCERT PHARMACEUTICALS, INC. 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058085-A1 Deuterium Modified Benzimidazoles POLRMT, EIF2AK2, DUT MEN1 4528/4885KMT2A 1259/4885LMNA 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.